Targeting chromatin regulators for the treatment of malignancies has shown great promise, but also revealed significant challenges. By employing an elegant shRNA screen and a selective pharmacological inhibitor, a recent study published in Nature establishes the bromodomain protein Brd4 as novel target in acute myeloid leukemia (AML).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659823 | PMC |
http://dx.doi.org/10.1016/j.ccr.2011.08.019 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!